Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy

Zeina Nabhan, Lori K St Dennis Feezle, Allen R. Kunselman, Nancy B. Johnson, Peter A. Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of post-treatment growth on AH. Study design: Medical records of girls with CPP were reviewed. Results: Twenty-six girls aged 7.2 ± 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60% of this growth. Conclusion: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of pre-dictability of growth after discontinuation of therapy suggests that the decision to stop treat-ment should be individualized.

Original languageEnglish
Pages (from-to)309-316
Number of pages8
JournalJournal of Pediatric Endocrinology and Metabolism
Volume22
Issue number4
StatePublished - Apr 2009

Fingerprint

Gonadotropin-Releasing Hormone
Growth
Therapeutics
Central Precocious Puberty
Statistical Factor Analysis
Medical Records

Keywords

  • Central precocious puberty
  • Final adult height
  • GnRa therapy

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy. / Nabhan, Zeina; Feezle, Lori K St Dennis; Kunselman, Allen R.; Johnson, Nancy B.; Lee, Peter A.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 22, No. 4, 04.2009, p. 309-316.

Research output: Contribution to journalArticle

Nabhan, Zeina ; Feezle, Lori K St Dennis ; Kunselman, Allen R. ; Johnson, Nancy B. ; Lee, Peter A. / Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy. In: Journal of Pediatric Endocrinology and Metabolism. 2009 ; Vol. 22, No. 4. pp. 309-316.
@article{b95fb8e5854c4760b0e2da5bbc105a26,
title = "Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy",
abstract = "Aim: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of post-treatment growth on AH. Study design: Medical records of girls with CPP were reviewed. Results: Twenty-six girls aged 7.2 ± 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60{\%} of this growth. Conclusion: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of pre-dictability of growth after discontinuation of therapy suggests that the decision to stop treat-ment should be individualized.",
keywords = "Central precocious puberty, Final adult height, GnRa therapy",
author = "Zeina Nabhan and Feezle, {Lori K St Dennis} and Kunselman, {Allen R.} and Johnson, {Nancy B.} and Lee, {Peter A.}",
year = "2009",
month = "4",
language = "English",
volume = "22",
pages = "309--316",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "4",

}

TY - JOUR

T1 - Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy

AU - Nabhan, Zeina

AU - Feezle, Lori K St Dennis

AU - Kunselman, Allen R.

AU - Johnson, Nancy B.

AU - Lee, Peter A.

PY - 2009/4

Y1 - 2009/4

N2 - Aim: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of post-treatment growth on AH. Study design: Medical records of girls with CPP were reviewed. Results: Twenty-six girls aged 7.2 ± 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60% of this growth. Conclusion: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of pre-dictability of growth after discontinuation of therapy suggests that the decision to stop treat-ment should be individualized.

AB - Aim: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of post-treatment growth on AH. Study design: Medical records of girls with CPP were reviewed. Results: Twenty-six girls aged 7.2 ± 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60% of this growth. Conclusion: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of pre-dictability of growth after discontinuation of therapy suggests that the decision to stop treat-ment should be individualized.

KW - Central precocious puberty

KW - Final adult height

KW - GnRa therapy

UR - http://www.scopus.com/inward/record.url?scp=67649359979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649359979&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 309

EP - 316

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 4

ER -